Podcasts about aace

Gareth McGlynn speaks with Nathan Schafer, Estimating Manager at Cornerstone General Contractors, at Advancing Preconstruction 2026 in Phoenix. A self-performing GC based in Alaska, Cornerstone gives Nathan a hands-on perspective on preconstruction that is grounded in real field conditions.Key Topics Covered:Nathan & Cornerstone: Working across healthcare, hospitality, and federal military projects, with a focus on vertical commercial construction.New Estimators & Value Engineering: The shortage of talent entering the field, their understanding of value engineering, and professional development through ASPE and AACE.Lean Construction: Its growing impact on the estimating process and the role of AI takeoff tools as a lean principle in action.Data Science in Preconstruction: How Cornerstone is incorporating data science into its workflow, including labor productivity tracking and predicting quantity growth risk as a function of design maturity.Value Management in Practice: Cornerstone's formal pilot on a $90M project: 13 propositions totaling $9M, with $7M accepted.You can connect with Nathan via his LinkedIn: https://www.linkedin.com/in/nathan-schafer-cpe-b75991178/Or reach him through his blog: https://www.preconomics.com/blog

Join endocrinologist Elizabeth Bauer, MD, FACP, FACE, DABOM, as she speaks with Michelle about her experience living with obesity, including the challenges, stigma, and turning points that shaped her path. Together, they explore the AACE Journey for Patients With Obesity, as Michelle shares which parts she found most helpful for understanding obesity as a chronic disease and navigating next steps. Don't miss this inspiring discussion, brought to you with the support of Boehringer-Ingelheim, Lilly, Novo Nordisk, and Amgen.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, recorded on-site at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Elizabeth Bauer, MD, a clinical endocrinologist and obesity specialist, to discuss key updates in obesity management presented during her “Year in Review” session at the AACE Annual Meeting. Bauer opens by highlighting AACE's updated obesity algorithm, released in late 2024, which builds on the organization's prior adiposity-based chronic disease framework and shifts obesity care further away from BMI-centered diagnosis toward a more comprehensive, disease-centric model. She explains the algorithm's emphasis on anthropometric assessment, adiposity distribution, and obesity staging, noting that clinicians must move beyond weight alone to better identify obesity-related complications and personalize treatment decisions.The discussion focuses on the algorithm's practical value, particularly its structured staging system and medication tables that help clinicians match pharmacotherapy to obesity-related comorbidities such as diabetes, MASLD, and obstructive sleep apnea. Bauer emphasizes that treatment goals should be complication-specific—for example, modest weight loss may improve glycemia, while greater total body weight reduction is needed for meaningful improvement in MASH. She and the hosts stress that obesity management should prioritize whole-person health rather than weight alone, drawing parallels to the evolution of diabetes treatment toward complication-driven care.The group then turns to emerging pharmacotherapies, with Bauer reviewing several phase 2 and 3 obesity trials involving newer incretin-based agents. She highlights mazdutide, a once-weekly GLP-1–based therapy studied in Chinese populations using lower BMI thresholds more reflective of Asian obesity risk, as well as combination therapies such as semaglutide plus cagrilintide, which demonstrated greater efficacy than semaglutide alone but with substantially higher gastrointestinal adverse effects. Bauer notes that while these agents show impressive weight loss potential, tolerability remains a major clinical challenge, particularly with nausea and dose escalation. A significant portion of the conversation centers on management of GI side effects from GLP-1 receptor agonists. Bauer explains her clinical philosophy of treating obesity like any other chronic disease—avoiding the routine practice of prescribing one medication to manage side effects caused by another whenever possible. While she may prescribe small, limited quantities of ondansetron during titration, she emphasizes that persistent nausea should prompt dose adjustment or medication changes rather than indefinite antiemetic use. The hosts discuss how slower titration strategies in real-world practice often improve tolerability compared with rigid clinical trial protocols and may help optimize long-acting monthly GLP-1 agents currently in development.The episode also reviews bariatric surgery data, including randomized trials comparing laparoscopic banding, sleeve gastrectomy, and Roux-en-Y gastric bypass. Bauer notes that both sleeve gastrectomy and Roux-en-Y demonstrated superior efficacy and fewer complications compared with lap band procedures, while long-term comparisons between sleeve and bypass showed strong outcomes for both, with Roux-en-Y numerically favoring weight loss but often without statistically significant superiority. She also discusses higher reoperation rates among patients initially undergoing sleeve gastrectomy, often due to inadequate weight loss or significant reflux requiring conversion to bypass.The conversation concludes with an important discussion on post-bariatric surgery weight regain and the growing use of GLP-1–based therapies after surgery. Bauer challenges the misconception that surgery “cures” obesity, emphasizing that obesity remains a chronic disease driven by persistent biology, inflammation, and environmental factors even after anatomical intervention. She notes emerging evidence suggesting that GLP-1 therapies used before or after bariatric surgery may improve long-term outcomes and reduce weight regain. She closes by reinforcing the need for clinicians to approach obesity with the same chronic disease mindset applied to diabetes—recognizing that durable management requires ongoing treatment, not a one-time intervention.

Join endocrine expert Vin Tangpricha, MD, PhD, as he moderates a discussion with members of the task force behind the updated 2026 AACE Consensus Statement: Algorithm for the Management of Adults with Type 2 Diabetes. AACE Past President and Chair Susan L. Samson, MD, PhD, FRCPC, FACE, is joined by Vice Chair Priyathama Vellanki, MD, along with Lawrence Blonde, MD, FACP, MACE, and Irl B. Hirsch, MD, MACP, to discuss key changes. Together, they explore how the new algorithm supports more individualized, complications-focused care and provides practical guidance clinicians can apply in everyday practice.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!On March 17, 2026, the American Association of Clinical Endocrinology (AACE) released a consensus statement, which features an algorithm for the management of type 2 diabetes (T2D) in adult patients.1In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review the newly released 2026 American Association of Clinical Endocrinology (AACE) type 2 diabetes treatment algorithm, positioning it as an evolution of the 2023 update that integrates a growing body of clinical trial evidence into a more comprehensive, complications-focused framework. They emphasize a paradigm shift away from glucose-centric management alone, highlighting the importance of addressing comorbidities, including cardiovascular disease, chronic kidney disease, obesity, obstructive sleep apnea, and metabolic dysfunction–associated steatotic liver disease (MASLD), as central to optimizing outcomes.The discussion outlines the guideline's structure, including its 10 guiding principles, which reinforce lifestyle intervention as foundational, promote individualized glycemic targets (with a preference for A1c ≤6.5% when safely achievable), and strongly encourage early use of continuous glucose monitoring (CGM). The hosts underscore the emphasis on avoiding therapeutic inertia, minimizing hypoglycemia risk, and managing cardiometabolic comorbidities alongside glycemia as part of routine care.A key highlight is the introduction of a diabetes classification algorithm aimed at reducing misdiagnosis, particularly distinguishing type 1 from type 2 diabetes and identifying less common etiologies. Within this framework, the guidelines newly prioritize screening for hypercortisolism, informed by findings from the CATALYST trial, which demonstrated a higher-than-expected prevalence among patients with difficult-to-control diabetes. Isaacs and Bellini note that recognizing and treating underlying hypercortisolism may significantly improve glycemic control and, in some cases, reduce the need for diabetes-specific therapies.The episode further reviews updated algorithms for cardiovascular risk reduction, dyslipidemia, and hypertension, emphasizing aggressive, individualized targets and the continued central role of lifestyle modification. Pharmacologic recommendations reflect robust recent evidence, prioritizing SGLT2 inhibitors and GLP-1 receptor agonists (including dual GIP/GLP-1 agents) for patients with cardiorenal or metabolic comorbidities, while also incorporating emerging indications such as heart failure with preserved ejection fraction and MASLD.Isaacs and Bellini also discuss the guideline's glucose-centric algorithm for patients without major comorbidities, highlighting patient-centered decision-making based on factors such as hypoglycemia risk, weight considerations, and cost/access. They reinforce recommendations for early combination therapy when A1c is significantly above target and appropriate use of insulin, including guidance on avoiding overbasalization and incorporating prandial strategies.The conversation concludes with commentary on the guideline's practical strengths, including clear visual algorithms, concise format, and detailed pharmacotherapy tables summarizing efficacy, safety, and organ-specific benefits. The hosts emphasize that the updated AACE algorithm provides clinicians with an actionable, evidence-based roadmap for delivering holistic, individualized diabetes care that extends beyond glycemic control to address the full spectrum of cardiometabolic risk.Editor's Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.ReferencesSamson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. Endocr Pract. Published online March 17, 2026. doi:10.1016/j.eprac.2026.01.006

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

What happens when 50 million people need endocrine care… but there are only about 4,000 practicing endocrinologists to see the complex cases? In an environment where misinformation is everywhere and specialist capacity is limited, how can an association help clinicians and care teams deliver better outcomes at scale without diluting quality?In this episode of Associations Thrive, host Joanna Pineda interviews Johnnie White, CEO of the American Association of Clinical Endocrinology (AACE). Johnnie discusses:How AACE's membership is ~6,000 worldwide, with predominantly physicians and a growing “endocrine care team” that includes NPs, PAs, pharmacists, and primary care clinicians.The sobering workforce math: “there's not enough endocrinologists” for the volume of diabetes (and other endocrine disorders), and why AACE prioritizes educating the broader care team.How members get access to endocrine-specific education, guidelines, publications, and networking with field experts.The strategic shift from “endocrinologists” to “endocrinology” and how a bigger tent supports care delivery while keeping endocrinologists as the clinical leaders who develop guidelines.AACE's patient-first digital strategy: landing visitors on the patient portal first, then routing clinicians to the healthcare/member portal.How AACE built “patient journeys” (diabetes, thyroid, obesity, and more) to counter misinformation and provide understandable, trustworthy guidance for patients and caregivers.Why AACE's patient content is heavily used not only by patients but also by clinicians who refer patients to it for education and reinforcement.The organization's non-traditional education mix, including podcasts as an accessible channel for timely topics, and microlearning with short modules, tracked for continuing education credit.Johnnie's leadership philosophy, “Mamba Mentality,” is a continuous quest to improve, seek feedback, and empower experts on the team.References:AACE Website

Join Dr. Steven Petak, Past President of AACE and ISCD and former Chief of Endocrinology at Houston Methodist Hospital, as he leads an in-depth conversation on Hypophosphatemia with Dr. Laila Tabatabai, Associate Professor of Clinical Medicine at Weill Cornell and metabolic bone specialist at Houston Methodist, and Dr. Basma Abdulhadi, Assistant Professor of Medicine at the University of Alabama at Birmingham and head of bone densitometry. Together, they discuss how to distinguish Hypophosphatemia from osteoporosis and osteomalacia, recognize key symptoms across ages, and apply a focused diagnostic workup. The discussion also highlights FGF23-mediated disorders, XLH, and current treatment approaches including burosumab, reinforcing a key reminder for clinicians to check phosphate levels to help prevent missed diagnoses. This episode is made possible through a sponsorship from Kyowa Kirin.Kyowa Kirin was not involved in the content of the podcast.

Karl Nadolsky, DO, and W. Timothy Garvey, MD, unpack several key points in the AACE's latest obesity management guidance.

Join endocrine expert Dr. David Lieb as he moderates a discussion with Dr. Karl Nadolsky, Chair of the AACE Obesity Algorithm, and Dr. Timothy Garvey, Vice Chair, as they review the 2025 AACE Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease and highlight key updates since 2016. The experts discuss advances in pharmacotherapy, the evolution of complication-centric and person-centered care, and strategies to reduce weight bias in clinical practice. They also share guidance on individualizing therapy and look ahead to the future of obesity medications as new treatments emerge.

Join endocrine expert Dr. David Lieb as he moderates a discussion with Dr. Shailendra Patel, Chair of the 2025 AACE Dyslipidemia Algorithm; Dr. Maria Belalcazar, Vice Chair; and Dr. Robert Hegele, Author and Representative of the Canadian Cardiovascular Society, about the 2025 Updated Algorithm for Management of Adults with Dyslipidemia.This episode covers:The rationale behind updating the algorithm and how it aligns with the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with DyslipidemiaKey updates from the 2020 algorithm, including expanded guidance on hypertriglyceridemia and lipid management in special populationsPractical strategies for integrating the algorithm into everyday clinical practice and medical education with an emphasis on patient-centered care, shared decision making, and health equityEmerging therapies on the horizon and priority areas for future research Tune in to hear expert insights on how this updated, evidence-based resource can support better clinical decision making and improve patient outcomes.

Join Dr. Cecilia Lansang, Associate Editor of Endocrine Practice, Professor of Medicine, and Director of Endocrinology at Cleveland Clinic, as she speaks with Dr. Kristen Flint, Interim Director of Quality and Safety for Endocrinology at Massachusetts General Hospital, Attending Endocrinologist at MGH, and Instructor at Harvard Medical School, about her team's quality improvement project, “Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care.” This episode covers:Strategies for implementing quality improvement interventions in a large academic diabetes specialty clinicKey interventions that increased CGM utilization, including targeted provider education, workflow optimization, and patient outreachLessons for advancing equitable implementation and sustaining quality improvement over time Tune in for practical insights on bridging policy changes and clinical practice to improve CGM access for Medicare patients. Read the full article in the August 2025 issue of Endocrine Practice here.

Join leading experts Fariha Abbasi-Feinberg, MD, FAASM, Medical Director of Sleep Medicine at Millennium Physician Group and President Elect for the American Academy of Sleep Medicine; Inderpreet K. Madahar, MD, MBBS, Assistant Professor of Endocrinology, Diabetes, and Metabolism at Corewell Health; and Sarah Nadeem, MD, FACE, Assistant Professor, Section of Endocrinology, Diabetes, and Metabolism at Baylor College of Medicine, Houston, TX, as they discuss the complex relationship between obstructive and central sleep apnea and metabolic disorders such as obesity and type 2 diabetes.Key topics include:Who should be screened for sleep apnea and the recommended screening toolsFirst-line and adjunctive therapies for managementThe evolving role of multidisciplinary careHow clinical practice is shifting with the recent FDA label expansion of tirzepatide (Zepbound®)When tirzepatide may be considered alongside or in place of CPAP, APAP, and BiPAP therapiesTune in for practical insights to better identify, manage, and support patients at risk. This episode is made possible through a sponsorship from Lilly.

Join Elizabeth M. Bauer, MD, FACP, FACE, Dipl ABOM, as she interviews Nicholas A. Tritos, MD, DSc, Professor of Clinical Medicine at Harvard Medical School and faculty of the Neuroendocrine Unit/Neuroendocrine and Pituitary Tumor Clinical Center at Massachusetts General Hospital, about his Endocrine Practice article, Impulse Control Disorders in Patients with Hyperprolactinemia on Dopamine Agonist Therapy – How Concerned Should We Be? The conversation explores the prevalence and risk factors for impulse control disorders, underlying biological mechanisms, clinical screening strategies, and approaches to patient counseling and management. Read the full article in the July 2025 issue of Endocrine Practice here: https://doi.org/10.1016/j.eprac.2025.04.018

La glande thyroïde intervient dans différentes fonctions du corps et ses dérèglements peuvent entraîner plusieurs problèmes de santé. Pour passer en revue les troubles les plus courants de la thyroïde et leurs traitements, Trait pharmacien reçoit Mary Ghattas, pharmacienne et cheffe adjointe du département de pharmacie du CISSS de Laval. Références : - Garber JR, Cobin RH, Gharib H et coll. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the AACE and ATA. Thyroid 2012;22:1200-35. - Ross DS, Burch HB, Cooper DS et coll. 2016 ATA guidelines for the diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343-421.

Join Dr. Laila Tabatabai, Chair of the AACE Bone and Parathyroid Disease State Network, for an expert-led discussion on how nutrition and exercise support bone health. She is joined by Dr. Deborah Sellmeyer, an internationally recognized endocrine expert in metabolic bone disease at Stanford University, and Rebekah Rotstein, founder of the Buff Bones® exercise system. Together, they explore:How much calcium and vitamin D are needed for bone healthThe benefits of weight-bearing, resistance, balance, and impact exercisesSupplements that support bone health, including vitamin K, magnesium, boron, and strontium, along with the potential benefits of prunesThe growing role of muscle strength, sarcopenia, and protein in osteoporosis care Whether you are a clinician or someone managing osteoporosis, this episode offers practical, evidence-based insights to help guide informed decisions.

Join clinical experts Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, Madhuri M. Vasudevan, MD, MPH, FACE, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, to learn how the AACE Patient Journey of Diabetes Technology supports people with diabetes in navigating their treatment options with confidence. This patient-friendly resource, developed from AACE clinical guidelines and reviewed by Diabetes Sisters, a leading patient advocacy organization, provides clear and accurate information on diabetes technologies, from glucose monitors to insulin delivery devices. The experts also highlight how members of the endocrine care team are using this tool to empower people with diabetes to manage their journey. This episode is brought to you with the support of Abbott, Novo Nordisk, Medtronic, and Vertex.

Join AACE Past President and endocrinologist Dr. Susan Samson as she leads a compelling roundtable discussion highlighting the importance of the endocrine care team model. She is joined by nurse practitioner Dominique Uva, physician associate Sonia Bahroo, nurse scientist and diabetes educator Dr. Julia Blanchette, endocrine pharmacist Dr. Diana Isaacs, and nurse practitioner and clinical professor Dr. Chris Yedinak. Together, they explore how multidisciplinary care teams are essential to addressing the growing burden of endocrine diseases such as diabetes and thyroid disorders. Each expert shares how they collaborate across disciplines to improve access, provide patient support, and extend specialist care, especially in underserved communities. Tune in for practical insights, collaborative strategies, and a deeper look into how team-based care can elevate endocrine health outcomes.

In this episode, Dr. Jaime Almandoz, Associate Professor of Medicine at UT Southwestern, is joined by Dr. Robert F. Kushner, Professor of Medicine at Northwestern University and a leading authority in obesity medicine, to discuss the recent Lancet Diabetes & Endocrinology Commission report, “Definition and Diagnostic Criteria of Clinical Obesity.” The report introduces a new framework for defining clinical and preclinical obesity, aiming to move beyond the limitations of BMI. Dr. Kushner shares insights into the Commission's global consensus process and how the updated definitions can transform care, reduce weight stigma, and support more targeted treatment. Don't miss this timely conversation on the evolving future of obesity diagnosis and management.

Join 2025 Annual Meeting Chair, Cecilia Low Wang, MD, FACP, FACE, as she interviews Rachna Relwani, MD, Chair of the Environmental Endocrinology Topic Interest Group (TIG), and David C. Lieb, MD, FACP, FACE, Chair of the Artificial Intelligence and Clinical Endocrinology TIG. In this episode, you'll gain insight into how these TIGs are advancing critical conversations, fostering collaboration through AACE's new Facebook Groups, and preparing for engaging meetups at the AACE Annual Meeting in Orlando, May 15–17. Whether you're passionate about environmental health or curious about the role of AI in clinical practice, this episode offers a dynamic preview of what's ahead.

Join Dr. David Lieb as he moderates a discussion with Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus Statement Task Force, and Dr. Michelle Lundholm, Methodology Fellow, about the recently released 2025 AACE Consensus Statement on the Management of Multiple Endocrine Neoplasia, Type 1 (MEN1).This episode covers:AACE's updated consensus statement methodology, including the new methodology fellow and patient representative rolesThe role of surgical and non-surgical management strategies for patients with different types of MEN1-related tumorsThe importance of patient values and preferences and risks/benefits of different screening modalities when determining appropriate screening frequencies for patientsCurrent gaps in the literature and future considerations for MEN1 research

Early detection and monitoring of Type 1 Diabetes (T1D) are crucial for improving patient outcomes and quality of life. Join clinical experts Lubaina S. Presswala, DO, FACOI, FACE; Jeff Unger, MD, FAAFP, FACE, DACD; and Javier Morales, MD, FACP, FACE, as they discuss the growing prevalence of T1D, the importance of autoantibody screening, the different stages of T1D, screening guidelines, patient counseling, and how early intervention can help delay progression and reduce complications. Support for this podcast is provided by Sanofi.

In this episode, join moderator Dr. David Lieb alongside esteemed panelists Dr. Shahnaz Sultan, Dr. Carol Peng, and Dr. Melanie Bird as they delve into the methodology behind the 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.Discover insights into:Why AACE adopted the GRADE framework and its implications for guideline development.The critical role of systematic reviews in creating evidence-based recommendations.How evidence is assessed using the GRADE approach.Practical takeaways for clinicians when implementing GRADE-informed guidelines in patient care.Whether you're a seasoned practitioner or new to the field, this discussion offers valuable perspectives on the evolution of evidence-based guideline development and its impact on clinical practice.

Join Dr. David Lieb as he moderates an engaging discussion with Dr. Shailendra Patel, Chair of the Dyslipidemia Guideline Task Force, and Dr. Kathleen Wyne, Vice Chair, about the recently released 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.This episode covers:What's new or different in this update compared to the 2017 guideline.Surprising insights revealed during the evidence assessments and how they shaped the recommendations.Key considerations for clinicians as they integrate these updated recommendations into practice.Gaps in the literature and opportunities for future research.Whether you're familiar with the previous guideline or new to this topic, this conversation provides a comprehensive overview of the latest advancements in dyslipidemia management.

Join endocrine expert Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, for a special AACE Podcast featuring her patient, Andree. Together, they explore Andree's personal journey with thyroid disease and how the AACE Journey for Patients With Thyroid Disease website has been an invaluable resource, offering clear and accessible tools to navigate her thyroid condition with confidence. Don't miss this inspiring discussion, brought to you with the support of AbbVie and Amgen Rare Disease.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, Director of Inpatient Diabetes at Long Island Jewish Medical Center, Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Northwell Health, and Chair Elect for the AACE 2025 Annual Meeting, as they discuss Dr. Schulman-Rosenbaum's EP article, “Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.” Tune in as they explore the complexities of managing inpatient hyperglycemia, the risks of SGLT-2 inhibitors in hospitalized patients, and who might be good candidates for safer alternatives like DPP-4 inhibitors and insulin. Packed with valuable insights and practical strategies, this discussion is essential for optimizing hospital-based diabetes care. Read the full article in the April 2024 issue of EP here.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Cecilia C. Low Wang, MD, FACE, FACP, Professor of Medicine and Medical Director for the Glucose Management Team at the University of Colorado, as they discuss Dr. Low Wang's impactful EP article titled "Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition." Tune in as they explore strategies for managing hyperglycemia and hypoglycemia in hospitalized patients on continuous tube feeds, evaluate insulin regimens such as 70/30 Q-8 hours and basal-bolus, examine differences in glycemia management for patients with and without diabetes, and discuss ways to optimize glycemic control. View the full article in the April 2024 issue of EP here.

Direto do Congresso Internacional do IBDiC, o Instituto Brasileiro de Direito da Construção, o Capital Projects Podcast traz mais uma série especial! Onde a Engenharia e o Direito se encontram, vocês terão aqui muitas discussões sobre temas ligados à gestão contratual e resolução de disputas! Nesse oitavo e penúltimo episódio da série, eu converso sobre arranjos colaborativos em Contratos de Construção com Rafael Monteiro. Rafael é sócio da prática de Infraestrutura & Projetos de Capital da Deloitte e Mestre em engenharia com foco em contratos internacionais de construção pela Universidade de Stuttgart. Liderou projetos no Brasil, Peru, México e Moçambique e dedica-se ao desenvolvimento de relações colaborativas entre investidores e construtores. É também membro da DRBF, AACE e SCL, e ganhador do Prêmio IBDiC 2023. Vamos falar sobre como podemos ter abordagens mais colaborativas entre Contratantes e Contratadas? Dê um play e vamos juntos! Para saber mais sobre os próximos eventos apoiados pelo Capital Projects Podcast, acesse: - 16° Congresso de Gestão, Projetos e Liderança do PMI MG, que vai acontecer em Belo Horizonte nos dias 22 e 23 de novembro: www.pmimg.org.br - 22° Seminário Internacional de Gerenciamento de Projetos do PMI SP, que vai acontecer nos dias 26 e 27 de novembro em São Paulo: www.pmisp.org.br (eu estarei lá!) - 23° Encontro de Gerenciamento de Projetos do PMI DF, que vai acontecer em Brasília de 26 a 28 de novembro: https://pmidf.org/egp/ Essa série só foi possível graças ao apoio especial da Deloitte (https://www.deloitte.com/br/pt.html) e do IBDiC (https://ibdic.org.br/)! Quer entrar no para saber em primeira mão sobre as lives e a nova turma do Curso GPI/FEL? Acesse: https://chat.whatsapp.com/KZNt0vR1zLfBt4ZeqflVGN #CapitalProjectsPodcast #GestãodeProjetos #CapitalProjects #AndreChoma #Construção #Engenharia #ProjectManagement #PMI #ProjectManagementInstitute #FEL #Frontendloading #MetodologiaFEL #Deloitte #IBDiC #GestãodeContratos #ContratosColaborativos #IPD #IntegratedProjectDelivery #RafaelMonteiro

Discover insights into the challenging landscape of Cushing syndrome, where adrenal variations require careful diagnostic and therapeutic strategies. In this podcast, Sina Jasim, MD, MPH, Editor-in-Chief of the AACE Clinical Reports (ACCR) and Associate Professor of Medicine at Washington University School of Medicine, leads a compelling discussion on two unique cases featured in the ACCR article, Histopathologic Differences Between Adrenocorticotropic Hormone–Dependent and Adrenocorticotropic Hormone–Independent Adrenal Hyperplasia Causing Cushing Syndrome. Authors, Amir H Hamrahian, MD, Endocrinologist, Associate Professor, and Medical Director of the Comprehensive Adrenal Center at Johns Hopkins University School of Medicine, and Ezra Baraban, MD, Assistant Professor of Pathology at Johns Hopkins University School of Medicine, explain the diagnostic challenges for each case, the decision-making process between medical and surgical approaches, and the critical role of pathology in guiding clinical care. Read the full case report in ACCR at https://www.aaceclinicalcasereports.com/article/S2376-0605(22)00066-9/fulltext.

Obesity is a complex, chronic disease of excessive or abnormally accumulated body fat that significantly increasing the risk of various medical conditions. As the most prevalent chronic disease in the United States—affecting 40% of the population—and impacting 1 in 8 people globally, finding reliable, clinically accurate, and patient-friendly information online can be challenging. To address this gap, AACE developed the “AACE Journey for Patients With Obesity,” a comprehensive resource designed to empower people with obesity to navigate their condition, treatment options, and wellness goals. In this episode, leading endocrinologists Elizabeth Bauer, MD, FACP; Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU; and Kenneth Izuora, MD, MBA, FACE, discuss the journey's development using the latest guidelines, including the integration of adiposity-based chronic disease (ABCD) terminology, which addresses the stigma associated with obesity. They also highlight the collaboration with the Obesity Action Coalition to ensure the resource is patient-centered and explain how both patients and health care professionals can utilize it to enhance care and improve outcomes. Support for this podcast was provided in part by Lilly and Boehringer Ingelheim.

Join Maria A. Mogollon, MSN, APRN, FNP-BC, a Diabetes and Obesity Nurse Practitioner and former Internal Medicine physician in Venezuela, and Jeff Unger, MD, FAAFP, FACE, DACD, Director, Unger Primary Care Concierge Medical Group, renowned Board-Certified Family Physician, Diabetologist, and co-author of the AACE 2021 Clinical Practice Guideline for the Use of Advanced Technology in the Management of Persons with Diabetes Mellitus, as they delve into crucial topics in diabetes technology. Key topics discussed include the benefits and cost-effectiveness of continuous glucose monitors (CGM) compared to traditional finger-stick methods, practical implementation into practice workflows, interpreting CGM data, and identifying ideal candidates for CGM use. Through case studies and practical examples, they address common concerns and barriers to CGM adoption, providing valuable insights for healthcare professionals on how to have effective conversations with patients and integrate CGM technology into patient care.

Join endocrine experts Ty Carroll, MD, Associate Professor of Medicine at the Medical College of Wisconsin, and Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, as they delve into Dr. Carroll's groundbreaking EP article titled "Hormonal Contraceptive Use Is Associated With a Decreased Incidence of Hypothyroidism." Tune in as they discuss the study findings on the association between hormonal contraceptive use and reduced hypothyroidism risk, along with its limitations and implications for future research. View the full article in the Jan. 2024 issue of EP at https://www.endocrinepractice.org/article/S1530-891X(23)00715-2/abstract.

The frequency of hematospermia in transgender women is unknown, indicating a gap in current medical understanding. Join medical experts Tamar Reisman, MD, Clinical Endocrinologist at New York Presbyterian Weill Cornell Medical Center, and Sina Jasim, MD, MPH, ACCR Editor-in-Chief and Associate Professor of Medicine at Washington University School of Medicine, as they delve into a groundbreaking clinical case report titled "Hematospermia in a Transgender Woman with Evidence for Endometrial Tissue in the Prostate." Tune in as they discuss the highlights of the case, when to screen for endometriosis or ectopic Müllerian epithelial tissue growth in transgender women undergoing feminizing gender-affirming hormone therapy, and how to address challenges and barriers to patient care. View the full report in the Jan. 2024 issue of ACCR at https://doi.org/10.1016/j.aace.2024.01.006.

Thyroid disease affects approximately 20 million Americans, leading many patients to turn to the internet for answers. However, amidst the vast array of information available online, distinguishing accurate information can be challenging. Recognizing this necessity, the endocrine experts at AACE have developed "The Journey For Patients With Thyroid Disease," an innovative resource devoted to educating and empowering individuals with thyroid disease to navigate their condition, treatment plan, and wellness goals. In this podcast, endocrine experts Alex Tessnow, MD, ECNU, FACE, Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, and Kenneth Izuora, MD, MBA, FACE, delve into the development, significance, and accessibility of this patient resource. Key topics discussed include the meticulous crafting of the journey into a meta-map using the latest AACE guidelines, the importance of providing patients with resources beyond the clinical setting, and how this resource serves as an invaluable tool for both patients and clinicians, providing timely updates on the latest clinical advancements for thyroid care. Support for this podcast was provided in part by AbbVie.

Join endocrine expert Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, and moderator Sina Jasim, MD, MPH, ACCR Editor-in-Chief, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine, as they discuss diabetes clinical case reports from the July/August 2023 issue of ACCR. Dr. McGill presents two key cases, MODY5 and Serous Ovarian Carcinoma in 17q12 Recurrent Deletion Syndrome, — a case of a young woman whose monogenic diabetes was diagnosed after a pathogenic ~1.8 Mb loss of 17q12 was found on the chromosomal microarray of her serous ovarian carcinoma and identifying a disease association not previously reported. The second case was on the maturity-onset of diabetes of the young (MODY), ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent, — a case of type 1 diabetes diagnoses during adolescence, and how the patient was treated with intensive insulin therapy for 17 years before genetic testing showed a pathogenic mutation of the ABCC8 gene. Access the key teaching points and view the full cases of MODY5 and Serous Ovarian Carcinoma in 17q12 Recurrent Deletion Syndrome at: https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00093-7/fulltext and ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent at: https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00086-X/fulltext

Parathyroid cysts (PC) are a rare cause of neck masses, with an ectopic intrathyroidal location being even more rare. Join endocrine experts Victor J. Bernet, MD, FACE, FACP, Director, Endocrinology, Diabetes and Metabolism Fellowship Program at the Mayo Clinic in Florida, and Sina Jasim,  MD, MPH, ACCR Editor-In-Chief, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine, as they discuss the clinical case report, A Middle-aged Woman With Recurrent Intrathyroidal Parathyroid Cyst Treated With Ethanol Sclerotherapy, which presents a case of a recurrent intrathyroidal cyst successfully treated with ethanol sclerotherapy. Key topics discussed include the sclerosis efficacy in orthotopically positioned PCs, how ethanol sclerotherapy is an effective treatment option for recurrent intrathyroidal PCs, and important teaching points of this case. Visit https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00131-1/fulltext to read the full AACE Clinical Case Report.

Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Global Liver Institute Founder and CEO Donna Cryer, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on Donna's personal health challenges in late 2023, what her absence revealed about the strength and depth of the GLI team, and what she foresees as major challenges for 2024. The conversation starts with Donna discussing a major medical event in her life during the last few months in 2024, one during which, in her words, "I almost died." She speaks briefly but clearly about the nature of the event itself, as well as how and why she is rebounding to full strength. Donna goes on to describe how well the GLI team performed in her absence and the various forms of feedback she received confirming this. In response to a question from Louise, she notes that building a strong team has always been her priority at GLI and cites several past examples where the team has led while she assumed other roles and challenges. From here, Donna notes a major change in 2023: the evolution from being a liver community to what she describes as "a community that cares about the liver," a multi-specialty, multi-stakeholder group focused on the wider implications of liver disease and patient and public health. As examples of this broader community, she cites the common guidelines from AACE and AASLD, conversations with payers and a willingness from other liver disease groups to share capabilities with the SLD community. She goes on to note that none of this change happens quickly, but that in the 10 years since GLI was formed, the scale of change has been consequential.The discussion turns toward the process of nomenclature change. Donna notes her concern throughout the process that some important implementation steps were not being considered on as timely or thorough a basis as she would have hoped. Specifically, she cites the issue of ICD codes and the need to involve primary care providers and organizations into the key processes. Louise Campbell agrees, noting the challenges around bringing wider use of VCTE into the UK system even after NICE has accepted the need to do so. Donna notes that this is the reason that GLI is calling its annual event Global Fatty Liver Day, not to be "recalcitrant, but because, as a global organization, we recognize" that not all parts of the world have adopted this nomenclature. She anticipates using what she calls "bridging documents" so that people using different nomenclatues can explain the same processes. From here, the conversation transitions to cover the growing momentum and energy in the patient and advocate communities, as evidenced by general energy and Roger's experience (along with Mike Betel) of getting pushed out of overflow rooms for patient sessions at AASLD (listen to E50.2 for more details). Finally, the conversation returns to the value of the MetALD classification, some issues around Donna's recent health scare, and a promising view of the future.

Surfing the MASH Tsunami continues its 2023 wrap-up conversations with hepatology researcher and key opinion leader Naim Alkhouri of the Arizona Liver Health Institute, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on viewing the year's major events in drug development, non-invasive tests (NITs) and clinical care pathways.This conversation starts with Roger asking Naim his reaction to 2023. Naim starts by mentioning his disappointment that OCA did not get approved but shares his vision that the data presentation did not support approval and his hope and belief that resmetirom will fare better. From there, he shifts quickly to discuss being "a little bit disappointed" at the implementation of the AACE and AGA guidelines. In practical terms, he has not seen a single referral from primary care practices (PCP) for elevated FIB-4. He notes that this will require better education of PCPs, but also expresses concern that the guidelines might not be practical for them. In the effort "not to miss a single patient," he believes, authors have created a system with too many patients screened, found negative, and sent back to the PCP. Instead, he suggests, guidelines should have a more realistic goal (reducing unidentified patients from 95% to 80%) and rely on higher FIB-4 cutoffs until PCPs have integrated the concept of MASH screening into their practices. Wrapping up his view of 2023, he describes it as a "good year," although unfortunately one in which drug approval and increased pathway use did not occur.Roger suggests that the same phenomenon -- worrying more about making things perfect than making them implementable -- applied to the original rollout of the new nomenclature as well as pathways, and goes on to discuss what he sees as the behavioral psychology implications of the pathway guidelines. Naim responds with two suggestions: raise the minimum PIB-4 score at which patients are referred to 2.67 and, in the US, reflex to an ELF test before sending patients to specialists. Louise notes that ELF is not as readily available in the UK as Americans might assume. Roger adds that it might be of value to educate PCPs on the value of FIB-4 as predictive of MACE and other forms of mortality.Roger asks Naim to describe the "biggest wins" of 2023. Naim starts by citing specific advances in NITs, specifically mentioning NIS-2+ and MASEF (discussed in S4 E39). In terms of medications, he discussed the double- and triple-incretin agonists and their ability to support patients in defatting their livers and notes that, of course, resmetirom's positive Phase 3 results are the biggest story. His third item is the expansion of multi-specialty meetings that educate other specialties on SLD, why it matters, and what roles the other specialties can play in diagnosing and managing MASH patients. Roger's next question is about disappointments. Naim wishes FDA had moved further and faster in alternate drug approval pathways and metrics, but sees progress in terms of their openness to exploring NITs and, more exciting, their recently stated willingness to grant full approvals in cirrhosis based on histology. Roger asks how AI fits into the emerging picture. Naim states that AI analyses can teach a great deal about the disease, but is not practical for patient treatment. The last question: his most optimistic picture for 2024 starts with resmetirom approval, goes on to mention several exciting potential drug development results and then discusses creating MASL Centers of Excellence relying on robust NITs for diagnosis and management. 

Minimally invasive procedures are now more widely used for benign and some low-risk cancerous thyroid tumors. In certain cases of papillary thyroid microcarcinomas; and if those are positioned in a favorable location, Radiofrequency Ablation (RFA) offers a less invasive treatment option compared to traditional surgical approaches. Listen to Leonardo Guimarães Rangel, MD, Head and Neck Surgeon in Rio de Janeiro, Brazil, and international expert in minimally invasive procedures in thyroid tumors, present his Visual Vignette on Radiofrequency Ablation of Papillary Thyroid Microcarcinomas,  moderated by Sina Jasim, MD, MPH, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine. Key topics include procedure safety, determining the right patient and nodule candidate, follow-up care, challenges, and future outcomes. Visit https://www.aaceclinicalcasereports.com/article/S2376-0605(22)00010-4/fulltext to view and read the full AACE Visual Vignette.

Join clinical experts David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE, as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed?” Key topics include how to put the guideline into practice particularly in primary care settings, how to characterize which people with diabetes should be prescribed glucagon to manage low blood sugar levels, and how to incorporate ready-to-use glucagon into hypoglycemia treatment plans for people with diabetes. Support for this podcast is provided by Xeris Pharmaceuticals, Inc.

Join endocrine experts Ricardo Correa, MD, FACP, FACMQ, FAPCR, FACE; Rajesh Garg, MD, PhD; and Geetha Gopalakrishnan, MD, FACE, as they share valuable tips and success stories on how to talk to patients with diabetes about the importance of vaccinations in diabetes management. Key topics include strategies for addressing barriers in workflows, differences in cultural norms and vaccine hesitancy. AACE endocrine experts share available patient resources along with a wealth of information aimed at enhancing your interactions with patients. 

AACE has revised its policies and adopted a new methodology for guideline and consensus statement development to support the mission to elevate the practice of clinical endocrinology to improve patient care. Join endocrine experts Ricardo Correa, MD, FACP, FACMQ, FAPCR, FACE, Joanna Miragaya, MD, PhD, FACE, and Vin Tangpricha, MD, PhD, FACE, as they dive into the 2023 protocol updates. Key topics include updates to methodology, processes, and policies. Visit https://www.endocrinepractice.org/article/S1530-891X(23)00032-0/fulltext to view the protocol in the May 2023 issue of Endocrine Practice.

Wolfram syndrome (WS) is a rare genetic disorder in which patients develop early-onset diabetes mellitus (DM), optic nerve atrophy, and neurodegeneration, which has no specific treatment available. Listen to endocrine experts Fumihiko Urano, MD, PhD. Samuel E. Schechter Professor of Medicine at Washington University School of Medicine, and Sina Jasim, MD, MPH, Associate Professor of Medicine at Washington University School of Medicine, discuss a new clinical case report on two patients with Wolfram syndrome who were initially diagnosed with type 1 diabetes but were negative for islet autoantibodies. Key topics include the importance of distinguishing between Wolfram syndrome and type 1 diabetes, the significance of the homozygous vs. compound heterozygous pathogenic variants in WFS1 gene, how the management and treatment for Wolfram syndrome differs from that of type 1 diabetes, the current status of therapeutic interventions, and much more. Visit https://doi.org/10.1016/j.aace.2022.01.001 to read the full AACE Clinical Case Report.

Today I am relasinng a podcast workshop I gave with the wonderful Janet McMordie of Second Act Actors Podcast live from the Association Of Actinf Educators and Coaches Conference.  If you have ever been curious about startgin your own podcast or wondered what goes on behind the scenes today's episode is sure to get your creative juices flowing. Enjoy!! Connect with Cue To Cue:  I: @thisischelseajohnson F: @thisischelseajohnson W https://thisischelseajohnson.com/

Join endocrine experts Karl Nadolsky, DO, DABOM, and Vin Tangpricha, MD, PhD, FACE, as they discuss the 2023 AACE Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity. Key topics include defining weight stigma, bias, and internalized weight bias (IWB), empowering patients and our global society to address obesity as a chronic disease, intervention recommendations using the 5A model, and much more. Visit https://www.endocrinepractice.org/article/S1530-891X(23)00335-X/fulltext to view the consensus statement in the June 2023 issue of Endocrine Practice.

In this What's Up Wednesday episode of the Gaining Health podcast, host Karli Burridge reviews some of the highlights of the American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update, which was released May 2023.Full the full Consensus Statement, click HERESupport the showThe Gaining Health Podcast will release a new episode monthly, every second Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer monthly and annual Memberships, which include live group coaching, a community forum to ask questions and post resources, pre-recorded Master Classes, digital resources inlcuding patient education materials and office forms, and much more! We also sell our popular Gaining Health products, including a book on developing an obesity management program, editable forms and templates, and patient education materials in our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

A wee bonus episode for you all! This is the live recording of my workshop at the AACE (Association of Acting Coaches & Educators) conference!Get ready to dive into the fascinating world of podcasting alongside Chelsea and I!In this lively session, we explore our captivating journey in the podcasting realm, uncovering secrets to becoming a stellar podcast guest or host. We'll also discuss the countless reasons why we adore this remarkable medium. Tune in now and bask in the joy of podcasting goodness! AACE websiteSecond Act ActorsCue To Cue Podcast Hosted on Acast. See acast.com/privacy for more information.

Are you an acting coach but can't find a community to guide you? Are you an acting educator who wants to update your teaching skills and knowledge?  In this week's episode, Actor/Painter/Teacher/Activist, Jennifer Wigmore would take us on a journey on how AACE was established to create a community amongst acting coaches and educators in Canada. AACE members share best practices and create standards for performers and workers in the entertainment industry. Together we can make acting training safer and  more empowering for everyone! In this episode: How an unfortunate casting experience evolved into Jennifer's green light to quit acting. How pursuing another artistic passion lead Jen to discover all creative endeavours are drawn from the same well. Just because you're a good actor doesn't mean you're a good teacher; sometimes your acting experience does not correlate into good teaching skills. The conversations about what we need to know as acting coaches and educators have changed so much that everyone needs to update their knowledge about how to create respect based classrooms and how not to hurt people. A little about Jennifer: Jennifer is a multidisciplinary artist in acting, writing, and visual art, and has worked for over twenty years as a professional artist. She has performed in theatre's across Canada including The Arts Club, Citadel Theatre, Tarragon Theatre, Theatre Center, Canadian Stage Company and the Stratford Festival. Jennifer has also appeared in numerous television series and films including; Dream Scenario, Christmas as the Drive In, The Winter Palace, Y: The Last Man, Malory Towers, Adult Adoption, Happy Place, Designated Survivor, Anne with an E, Impulse, Killjoys, Suits, Kart Racer, Little Men, and I Was a Sixth Grade Alien. She has just been cast as Chief April Anderson in the highly anticipated series Cross, based on James Pattersons novels, starring Aldis Hodge. She also narrated Todd Babiak's novel, The Spirits Up. She completed her BFA and MFA at OCAD University and continues to work as an acting coach and educator as well as a painting instructor. In addition to being a core member of the activist group Got Your Back, Jennifer is also a coordinator and steering committee member for AACE – The Association of Acting Coaches and Educators. Jennifer is also currently writing her first play called Measure Follow Jennifer! Online: jenniferwigmore.com,  aactingcoacheseducators.com Instagram: @jenniferwigmore @jenniferwigmoreart @aactingcoacheseducators Facebook: Jennifer Wigmore Jennifer Wigmore Art AACE – Association of Acting Coaches and Educators  

Join endocrine experts Irl Hirsch, MD, Susan L. Samson, M.D., Ph.D., FRCPC, FACE, and Vin Tangpricha, MD, PhD, FACE, as they discuss the latest updates to AACE's 2023 diabetes algorithm, which provides concise guidance to assist health care professionals in clinical decision-making for the management of Type 2 diabetes (T2D). Learn how to leverage the algorithm to improve patient care, how someone's risk for hypoglycemia impacts their individual target, when to use a complications-centric and glucose-centric approach to choosing first-line therapy for glycemic control, and much more. Visit https://doi.org/10.1016/j.eprac.2023.02.001 to view the full algorithm in the May 2023 issue of Endocrine Practice.

Credits: 0.25 AMA PRA Category 1 Credit™     CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-302   Overview: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, with a prevalence rate of more than 30% of US adults. Most have not been diagnosed or treated. Join us to discuss the new AACE guidance on the diagnosis and treatment of NAFLD to reduce the burden of this common disease.   Episode resource links: AACE Guideline:  Endocrine Pract: May 2022, 28(5): 528-562 Coffee: Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596   Guest: Robert A. Baldor, MD   Music Credit: Richard Onorato